APO Research
Talk to an analyst

APO RESEARCH · REPORT

Tachykinin Receptor 1 Antibody

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Tachykinin Receptor 1 Antibody Market Outlook and Growth Opportunities 2026

19 December 2025199 pages

Choose your research edition.

Industry ResearchTachykinin Receptor 1 Antibody Industry Research Report 2026120 pages · $2,950 USDIndustry Growth & TrendsGlobal Tachykinin Receptor 1 Antibody Industry Growth and Trends Forecast to 2032102 pages · $3,450 USDMarket StructureGlobal Tachykinin Receptor 1 Antibody Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032196 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Tachykinin Receptor 1 Antibody Market Outlook and Growth Opportunities 2026199 pages · $4,250 USDMarket Analysis & ForecastGlobal Tachykinin Receptor 1 Antibody Market Analysis and Forecast 2026-2032194 pages · $4,950 USD

Market perspective

The global Tachykinin Receptor 1 Antibody market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Tachykinin Receptor 1 Antibody is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Tachykinin Receptor 1 Antibody is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Tachykinin Receptor 1 Antibody is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Tachykinin Receptor 1 Antibody market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Tachykinin Receptor 1 Antibody market include Merck, Boster Biological Technology, United States Biological, Santa Cruz Biotechnology, Proteintech, ProSci, NSJ Bioreagents, LSBio and GeneTex, among others. In 2025, the top three vendors together accounted for approximately % of global market revenue.

This report provides an overview of the global Tachykinin Receptor 1 Antibody market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Tachykinin Receptor 1 Antibody and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Tachykinin Receptor 1 Antibody revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global Tachykinin Receptor 1 Antibody market.

Tachykinin Receptor 1 Antibody Segment by Company

Merck

Boster Biological Technology

United States Biological

Santa Cruz Biotechnology

Proteintech

ProSci

NSJ Bioreagents

LSBio

GeneTex

FineTest

Everest Biotech

Cusabio

Atlas Antibodies

Advanced Targeting Solutions

Tachykinin Receptor 1 Antibody Segment by Type

Polyclonal

Monoclonal

Tachykinin Receptor 1 Antibody Segment by Application

Western Blot

Flow Cytometry

Immunocytochemistry

Immunofluorescence

Others

Tachykinin Receptor 1 Antibody Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global Tachykinin Receptor 1 Antibody status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the Tachykinin Receptor 1 Antibody key companies, revenue, market share, and recent developments.

3. To split the Tachykinin Receptor 1 Antibody breakdown data by regions, type, companies, and application.

4. To analyze the global and key regions Tachykinin Receptor 1 Antibody market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Tachykinin Receptor 1 Antibody significant trends, drivers, influence factors in global and regions.

6. To analyze Tachykinin Receptor 1 Antibody competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Tachykinin Receptor 1 Antibody market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Tachykinin Receptor 1 Antibody and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Tachykinin Receptor 1 Antibody.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Tachykinin Receptor 1 Antibody industry.

Chapter 3: Detailed analysis of Tachykinin Receptor 1 Antibody company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales value of Tachykinin Receptor 1 Antibody in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.

Chapter 7: Sales value of Tachykinin Receptor 1 Antibody in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 9: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Tachykinin Receptor 1 Antibody Industry Trends Table 2. Tachykinin Receptor 1 Antibody Industry Drivers Table 3. Tachykinin Receptor 1 Antibody Industry Opportunities and Challenges Table 4. Tachykinin Receptor 1 Antibody Industry Restraints Table 5. Global Tachykinin Receptor 1 Antibody Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Tachykinin Receptor 1 Antibody Revenue Share by Company (2021-2026) Table 7. Global Tachykinin Receptor 1 Antibody Company Ranking, (2024-2026) & (US$ Million) Table 8. Global Tachykinin Receptor 1 Antibody Key Company Manufacturing Base & Headquarters Table 9. Global Tachykinin Receptor 1 Antibody Company, Product Type & Application Table 10. Global Tachykinin Receptor 1 Antibody Company Establishment Date Table 11. Global Company Market Concentration Ratio (CR5 and HHI) Table 12. Global Tachykinin Receptor 1 Antibody by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 13. Mergers & Acquisitions, Expansion Table 14. Significant Companies of Polyclonal Table 15. Significant Companies of Monoclonal Table 16. Global Tachykinin Receptor 1 Antibody Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 17. Global Tachykinin Receptor 1 Antibody Sales Value by Type (2021-2026) & (US$ Million) Table 18. Global Tachykinin Receptor 1 Antibody Sales Value by Type (2027-2032) & (US$ Million) Table 19. Global Tachykinin Receptor 1 Antibody Sales Value Share by Type (2021-2026) Table 20. Global Tachykinin Receptor 1 Antibody Sales Value Share by Type (2027-2032) Table 21. Significant Companies of Western Blot Table 22. Significant Companies of Flow Cytometry Table 23. Significant Companies of Immunocytochemistry Table 24. Significant Companies of Immunofluorescence Table 25. Significant Companies of Others Table 26. Global Tachykinin Receptor 1 Antibody Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 27. Global Tachykinin Receptor 1 Antibody Sales Value by Application (2021-2026) & (US$ Million) Table 28. Global Tachykinin Receptor 1 Antibody Sales Value by Application (2027-2032) & (US$ Million) Table 29. Global Tachykinin Receptor 1 Antibody Sales Value Share by Application (2021-2026) Table 30. Global Tachykinin Receptor 1 Antibody Sales Value Share by Application (2027-2032) Table 31. Global Tachykinin Receptor 1 Antibody Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 32. Global Tachykinin Receptor 1 Antibody Sales Value by Region (2021-2026) & (US$ Million) Table 33. Global Tachykinin Receptor 1 Antibody Sales Value Share by Region (2021-2026) Table 34. Global Tachykinin Receptor 1 Antibody Sales Value by Region (2027-2032) & (US$ Million) Table 35. Global Tachykinin Receptor 1 Antibody Sales Value Share by Region (2027-2032) Table 36. Global Tachykinin Receptor 1 Antibody Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 37. Global Tachykinin Receptor 1 Antibody Sales Value by Country (2021-2026) & (US$ Million) Table 38. Global Tachykinin Receptor 1 Antibody Sales Value Market Share by Country (2021-2026) Table 39. Global Tachykinin Receptor 1 Antibody Sales Value by Country (2027-2032) & (US$ Million) Table 40. Global Tachykinin Receptor 1 Antibody Sales Value Market Share by Country (2027-2032) Table 41. Merck Company Information Table 42. Merck Business Overview Table 43. Merck Tachykinin Receptor 1 Antibody Revenue (US$ Million) and Gross Margin (2021-2026) Table 44. Merck Tachykinin Receptor 1 Antibody Product Portfolio Table 45. Merck Recent Development Table 46. Boster Biological Technology Company Information Table 47. Boster Biological Technology Business Overview Table 48. Boster Biological Technology Tachykinin Receptor 1 Antibody Revenue (US$ Million) and Gross Margin (2021-2026) Table 49. Boster Biological Technology Tachykinin Receptor 1 Antibody Product Portfolio Table 50. Boster Biological Technology Recent Development Table 51. United States Biological Company Information Table 52. United States Biological Business Overview Table 53. United States Biological Tachykinin Receptor 1 Antibody Revenue (US$ Million) and Gross Margin (2021-2026) Table 54. United States Biological Tachykinin Receptor 1 Antibody Product Portfolio Table 55. United States Biological Recent Development Table 56. Santa Cruz Biotechnology Company Information Table 57. Santa Cruz Biotechnology Business Overview Table 58. Santa Cruz Biotechnology Tachykinin Receptor 1 Antibody Revenue (US$ Million) and Gross Margin (2021-2026) Table 59. Santa Cruz Biotechnology Tachykinin Receptor 1 Antibody Product Portfolio Table 60. Santa Cruz Biotechnology Recent Development Table 61. Proteintech Company Information Table 62. Proteintech Business Overview Table 63. Proteintech Tachykinin Receptor 1 Antibody Revenue (US$ Million) and Gross Margin (2021-2026) Table 64. Proteintech Tachykinin Receptor 1 Antibody Product Portfolio Table 65. Proteintech Recent Development Table 66. ProSci Company Information Table 67. ProSci Business Overview Table 68. ProSci Tachykinin Receptor 1 Antibody Revenue (US$ Million) and Gross Margin (2021-2026) Table 69. ProSci Tachykinin Receptor 1 Antibody Product Portfolio Table 70. ProSci Recent Development Table 71. NSJ Bioreagents Company Information Table 72. NSJ Bioreagents Business Overview Table 73. NSJ Bioreagents Tachykinin Receptor 1 Antibody Revenue (US$ Million) and Gross Margin (2021-2026) Table 74. NSJ Bioreagents Tachykinin Receptor 1 Antibody Product Portfolio Table 75. NSJ Bioreagents Recent Development Table 76. LSBio Company Information Table 77. LSBio Business Overview Table 78. LSBio Tachykinin Receptor 1 Antibody Revenue (US$ Million) and Gross Margin (2021-2026) Table 79. LSBio Tachykinin Receptor 1 Antibody Product Portfolio Table 80. LSBio Recent Development Table 81. GeneTex Company Information Table 82. GeneTex Business Overview Table 83. GeneTex Tachykinin Receptor 1 Antibody Revenue (US$ Million) and Gross Margin (2021-2026) Table 84. GeneTex Tachykinin Receptor 1 Antibody Product Portfolio Table 85. GeneTex Recent Development Table 86. FineTest Company Information Table 87. FineTest Business Overview Table 88. FineTest Tachykinin Receptor 1 Antibody Revenue (US$ Million) and Gross Margin (2021-2026) Table 89. FineTest Tachykinin Receptor 1 Antibody Product Portfolio Table 90. FineTest Recent Development Table 91. Everest Biotech Company Information Table 92. Everest Biotech Business Overview Table 93. Everest Biotech Tachykinin Receptor 1 Antibody Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 94. Everest Biotech Tachykinin Receptor 1 Antibody Product Portfolio Table 95. Everest Biotech Recent Development Table 96. Cusabio Company Information Table 97. Cusabio Business Overview Table 98. Cusabio Tachykinin Receptor 1 Antibody Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 99. Cusabio Tachykinin Receptor 1 Antibody Product Portfolio Table 100. Cusabio Recent Development Table 101. Atlas Antibodies Company Information Table 102. Atlas Antibodies Business Overview Table 103. Atlas Antibodies Tachykinin Receptor 1 Antibody Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 104. Atlas Antibodies Tachykinin Receptor 1 Antibody Product Portfolio Table 105. Atlas Antibodies Recent Development Table 106. Advanced Targeting Solutions Company Information Table 107. Advanced Targeting Solutions Business Overview Table 108. Advanced Targeting Solutions Tachykinin Receptor 1 Antibody Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 109. Advanced Targeting Solutions Tachykinin Receptor 1 Antibody Product Portfolio Table 110. Advanced Targeting Solutions Recent Development Table 111. Research Programs/Design for This Report Table 112. Authors List of This Report Table 113. Secondary Sources Table 114. Primary Sources List of Figures Figure 1. Tachykinin Receptor 1 Antibody Product Image Figure 2. Global Tachykinin Receptor 1 Antibody Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Tachykinin Receptor 1 Antibody Market Size (2021-2032) & (US$ Million) Figure 4. Global Tachykinin Receptor 1 Antibody Company Revenue Ranking in 2025 (US$ Million) Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 7. Polyclonal Image Figure 8. Monoclonal Image Figure 9. Global Tachykinin Receptor 1 Antibody Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 10. Global Tachykinin Receptor 1 Antibody Sales Value Share 2021 VS 2025 VS 2032 Figure 11. Global Tachykinin Receptor 1 Antibody Sales Value Share by Type (2021-2032) Figure 12. Western Blot Image Figure 13. Flow Cytometry Image Figure 14. Immunocytochemistry Image Figure 15. Immunofluorescence Image Figure 16. Others Image Figure 17. Global Tachykinin Receptor 1 Antibody Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 18. Global Tachykinin Receptor 1 Antibody Sales Value Share 2021 VS 2025 VS 2032 Figure 19. Global Tachykinin Receptor 1 Antibody Sales Value Share by Application (2021-2032) Figure 20. Global Tachykinin Receptor 1 Antibody Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 21. Global Tachykinin Receptor 1 Antibody Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 22. North America Tachykinin Receptor 1 Antibody Sales Value (2021-2032) & (US$ Million) Figure 23. North America Tachykinin Receptor 1 Antibody Sales Value Share by Country (%), 2025 VS 2032 Figure 24. Europe Tachykinin Receptor 1 Antibody Sales Value (2021-2032) & (US$ Million) Figure 25. Europe Tachykinin Receptor 1 Antibody Sales Value Share by Country (%), 2025 VS 2032 Figure 26. Asia-Pacific Tachykinin Receptor 1 Antibody Sales Value (2021-2032) & (US$ Million) Figure 27. Asia-Pacific Tachykinin Receptor 1 Antibody Sales Value Share by Country (%), 2025 VS 2032 Figure 28. South America Tachykinin Receptor 1 Antibody Sales Value (2021-2032) & (US$ Million) Figure 29. South America Tachykinin Receptor 1 Antibody Sales Value Share by Country (%), 2025 VS 2032 Figure 30. Middle East & Africa Tachykinin Receptor 1 Antibody Sales Value (2021-2032) & (US$ Million) Figure 31. Middle East & Africa Tachykinin Receptor 1 Antibody Sales Value Share by Country (%), 2025 VS 2032 Figure 32. USA Tachykinin Receptor 1 Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 33. USA Tachykinin Receptor 1 Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 34. USA Tachykinin Receptor 1 Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 35. Canada Tachykinin Receptor 1 Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 36. Canada Tachykinin Receptor 1 Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 37. Canada Tachykinin Receptor 1 Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 38. Mexico Tachykinin Receptor 1 Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 39. Mexico Tachykinin Receptor 1 Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 40. Mexico Tachykinin Receptor 1 Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 41. Germany Tachykinin Receptor 1 Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 42. Germany Tachykinin Receptor 1 Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 43. Germany Tachykinin Receptor 1 Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 44. France Tachykinin Receptor 1 Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 45. France Tachykinin Receptor 1 Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 46. France Tachykinin Receptor 1 Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 47. U.K. Tachykinin Receptor 1 Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 48. U.K. Tachykinin Receptor 1 Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 49. U.K. Tachykinin Receptor 1 Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 50. Italy Tachykinin Receptor 1 Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 51. Italy Tachykinin Receptor 1 Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 52. Italy Tachykinin Receptor 1 Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 53. Spain Tachykinin Receptor 1 Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 54. Spain Tachykinin Receptor 1 Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 55. Spain Tachykinin Receptor 1 Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 56. Russia Tachykinin Receptor 1 Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 57. Russia Tachykinin Receptor 1 Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 58. Russia Tachykinin Receptor 1 Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 59. Netherlands Tachykinin Receptor 1 Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 60. Netherlands Tachykinin Receptor 1 Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 61. Netherlands Tachykinin Receptor 1 Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 62. Nordic Countries Tachykinin Receptor 1 Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 63. Nordic Countries Tachykinin Receptor 1 Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 64. Nordic Countries Tachykinin Receptor 1 Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 65. China Tachykinin Receptor 1 Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 66. China Tachykinin Receptor 1 Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 67. China Tachykinin Receptor 1 Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 68. Japan Tachykinin Receptor 1 Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 69. Japan Tachykinin Receptor 1 Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 70. Japan Tachykinin Receptor 1 Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 71. South Korea Tachykinin Receptor 1 Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 72. South Korea Tachykinin Receptor 1 Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 73. South Korea Tachykinin Receptor 1 Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 74. India Tachykinin Receptor 1 Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 75. India Tachykinin Receptor 1 Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 76. India Tachykinin Receptor 1 Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 77. Australia Tachykinin Receptor 1 Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 78. Australia Tachykinin Receptor 1 Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 79. Australia Tachykinin Receptor 1 Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 80. Southeast Asia Tachykinin Receptor 1 Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 81. Southeast Asia Tachykinin Receptor 1 Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 82. Southeast Asia Tachykinin Receptor 1 Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 83. Brazil Tachykinin Receptor 1 Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 84. Brazil Tachykinin Receptor 1 Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 85. Brazil Tachykinin Receptor 1 Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 86. Argentina Tachykinin Receptor 1 Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 87. Argentina Tachykinin Receptor 1 Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 88. Argentina Tachykinin Receptor 1 Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 89. Chile Tachykinin Receptor 1 Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 90. Chile Tachykinin Receptor 1 Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 91. Chile Tachykinin Receptor 1 Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 92. Colombia Tachykinin Receptor 1 Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 93. Colombia Tachykinin Receptor 1 Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 94. Colombia Tachykinin Receptor 1 Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 95. Peru Tachykinin Receptor 1 Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 96. Peru Tachykinin Receptor 1 Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 97. Peru Tachykinin Receptor 1 Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 98. Saudi Arabia Tachykinin Receptor 1 Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 99. Saudi Arabia Tachykinin Receptor 1 Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 100. Saudi Arabia Tachykinin Receptor 1 Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 101. Israel Tachykinin Receptor 1 Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 102. Israel Tachykinin Receptor 1 Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 103. Israel Tachykinin Receptor 1 Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 104. UAE Tachykinin Receptor 1 Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 105. UAE Tachykinin Receptor 1 Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 106. UAE Tachykinin Receptor 1 Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 107. Turkey Tachykinin Receptor 1 Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 108. Turkey Tachykinin Receptor 1 Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 109. Turkey Tachykinin Receptor 1 Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 110. Iran Tachykinin Receptor 1 Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 111. Iran Tachykinin Receptor 1 Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 112. Iran Tachykinin Receptor 1 Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 113. Egypt Tachykinin Receptor 1 Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 114. Egypt Tachykinin Receptor 1 Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 115. Egypt Tachykinin Receptor 1 Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 116. Years Considered Figure 117. Research Process Figure 118. Key Executives Interviewed

Scope & coverage.

Types
  • Polyclonal
  • Monoclonal
Applications
  • Western Blot
  • Flow Cytometry
  • Immunocytochemistry
  • Immunofluorescence
  • Others
Companies covered
  • Merck
  • Boster Biological Technology
  • United States Biological
  • Santa Cruz Biotechnology
  • Proteintech
  • ProSci
  • NSJ Bioreagents
  • LSBio
  • GeneTex
  • FineTest
  • Everest Biotech
  • Cusabio
  • Atlas Antibodies
  • Advanced Targeting Solutions

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Tachykinin Receptor 1 Antibody Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Tachykinin Receptor 1 Antibody Market Size (2021-2032)
  4. 1.4 Assumptions and Limitations
  5. 1.5 Study Goals and Objectives
2 Tachykinin Receptor 1 Antibody Market Dynamics
  1. 2.1 Tachykinin Receptor 1 Antibody Industry Trends
  2. 2.2 Tachykinin Receptor 1 Antibody Industry Drivers
  3. 2.3 Tachykinin Receptor 1 Antibody Industry Opportunities and Challenges
  4. 2.4 Tachykinin Receptor 1 Antibody Industry Restraints
3 Tachykinin Receptor 1 Antibody Market by Company
  1. 3.1 Global Tachykinin Receptor 1 Antibody Company Revenue Ranking in 2025
  2. 3.2 Global Tachykinin Receptor 1 Antibody Revenue by Company (2021-2026)
  3. 3.3 Global Tachykinin Receptor 1 Antibody Company Ranking (2024-2026)
  4. 3.4 Global Tachykinin Receptor 1 Antibody Company Manufacturing Base and Headquarters
  5. 3.5 Global Tachykinin Receptor 1 Antibody Company Product Type and Application
  6. 3.6 Global Tachykinin Receptor 1 Antibody Company Establishment Date
  7. 3.7 Market Competitive Analysis
  8. 3.7.1 Global Tachykinin Receptor 1 Antibody Market Concentration Ratio (CR5 and HHI)
  9. 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  10. 3.7.3 2025 Tachykinin Receptor 1 Antibody Tier 1, Tier 2, and Tier 3 Companies
  11. 3.8 Mergers and Acquisitions Expansion
4 Tachykinin Receptor 1 Antibody Market by Type
  1. 4.1 Tachykinin Receptor 1 Antibody Type Introduction
  2. 4.1.1 Polyclonal
  3. 4.1.2 Monoclonal
  4. 4.2 Global Tachykinin Receptor 1 Antibody Sales Value by Type
  5. 4.2.1 Global Tachykinin Receptor 1 Antibody Sales Value by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global Tachykinin Receptor 1 Antibody Sales Value by Type (2021-2032)
  7. 4.2.3 Global Tachykinin Receptor 1 Antibody Sales Value Share by Type (2021-2032)
5 Tachykinin Receptor 1 Antibody Market by Application
  1. 5.1 Tachykinin Receptor 1 Antibody Application Introduction
  2. 5.1.1 Western Blot
  3. 5.1.2 Flow Cytometry
  4. 5.1.3 Immunocytochemistry
  5. 5.1.4 Immunofluorescence
  6. 5.1.5 Others
  7. 5.2 Global Tachykinin Receptor 1 Antibody Sales Value by Application
  8. 5.2.1 Global Tachykinin Receptor 1 Antibody Sales Value by Application (2021 VS 2025 VS 2032)
  9. 5.2.2 Global Tachykinin Receptor 1 Antibody Sales Value by Application (2021-2032)
  10. 5.2.3 Global Tachykinin Receptor 1 Antibody Sales Value Share by Application (2021-2032)
6 Tachykinin Receptor 1 Antibody Regional Value Analysis
  1. 6.1 Global Tachykinin Receptor 1 Antibody Sales Value by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Tachykinin Receptor 1 Antibody Sales Value by Region (2021-2032)
  3. 6.2.1 Global Tachykinin Receptor 1 Antibody Sales Value by Region: 2021-2026
  4. 6.2.2 Global Tachykinin Receptor 1 Antibody Sales Value by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Tachykinin Receptor 1 Antibody Sales Value (2021-2032)
  7. 6.3.2 North America Tachykinin Receptor 1 Antibody Sales Value Share by Country, 2025 VS 2032
  8. 6.4 Europe
  9. 6.4.1 Europe Tachykinin Receptor 1 Antibody Sales Value (2021-2032)
  10. 6.4.2 Europe Tachykinin Receptor 1 Antibody Sales Value Share by Country, 2025 VS 2032
  11. 6.5 Asia-Pacific
  12. 6.5.1 Asia-Pacific Tachykinin Receptor 1 Antibody Sales Value (2021-2032)
  13. 6.5.2 Asia-Pacific Tachykinin Receptor 1 Antibody Sales Value Share by Country, 2025 VS 2032
  14. 6.6 South America
  15. 6.6.1 South America Tachykinin Receptor 1 Antibody Sales Value (2021-2032)
  16. 6.6.2 South America Tachykinin Receptor 1 Antibody Sales Value Share by Country, 2025 VS 2032
  17. 6.7 Middle East & Africa
  18. 6.7.1 Middle East & Africa Tachykinin Receptor 1 Antibody Sales Value (2021-2032)
  19. 6.7.2 Middle East & Africa Tachykinin Receptor 1 Antibody Sales Value Share by Country, 2025 VS 2032
7 Tachykinin Receptor 1 Antibody Country-level Value Analysis
  1. 7.1 Global Tachykinin Receptor 1 Antibody Sales Value by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Tachykinin Receptor 1 Antibody Sales Value by Country (2021-2032)
  3. 7.2.1 Global Tachykinin Receptor 1 Antibody Sales Value by Country (2021-2026)
  4. 7.2.2 Global Tachykinin Receptor 1 Antibody Sales Value by Country (2027-2032)
  5. 7.3 USA
  6. 7.3.1 USA Tachykinin Receptor 1 Antibody Sales Value Growth Rate (2021-2032)
  7. 7.3.2 USA Tachykinin Receptor 1 Antibody Sales Value Share by Type, 2025 VS 2032
  8. 7.3.3 USA Tachykinin Receptor 1 Antibody Sales Value Share by Application, 2025 VS 2032
  9. 7.4 Canada
  10. 7.4.1 Canada Tachykinin Receptor 1 Antibody Sales Value Growth Rate (2021-2032)
  11. 7.4.2 Canada Tachykinin Receptor 1 Antibody Sales Value Share by Type, 2025 VS 2032
  12. 7.4.3 Canada Tachykinin Receptor 1 Antibody Sales Value Share by Application, 2025 VS 2032
  13. 7.5 Mexico
  14. 7.5.1 Mexico Tachykinin Receptor 1 Antibody Sales Value Growth Rate (2021-2032)
  15. 7.5.2 Mexico Tachykinin Receptor 1 Antibody Sales Value Share by Type, 2025 VS 2032
  16. 7.5.3 Mexico Tachykinin Receptor 1 Antibody Sales Value Share by Application, 2025 VS 2032
  17. 7.6 Germany
  18. 7.6.1 Germany Tachykinin Receptor 1 Antibody Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Germany Tachykinin Receptor 1 Antibody Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Germany Tachykinin Receptor 1 Antibody Sales Value Share by Application, 2025 VS 2032
  21. 7.7 France
  22. 7.7.1 France Tachykinin Receptor 1 Antibody Sales Value Growth Rate (2021-2032)
  23. 7.7.2 France Tachykinin Receptor 1 Antibody Sales Value Share by Type, 2025 VS 2032
  24. 7.7.3 France Tachykinin Receptor 1 Antibody Sales Value Share by Application, 2025 VS 2032
  25. 7.8 U.K.
  26. 7.8.1 U.K. Tachykinin Receptor 1 Antibody Sales Value Growth Rate (2021-2032)
  27. 7.8.2 U.K. Tachykinin Receptor 1 Antibody Sales Value Share by Type, 2025 VS 2032
  28. 7.8.3 U.K. Tachykinin Receptor 1 Antibody Sales Value Share by Application, 2025 VS 2032
  29. 7.9 Italy
  30. 7.9.1 Italy Tachykinin Receptor 1 Antibody Sales Value Growth Rate (2021-2032)
  31. 7.9.2 Italy Tachykinin Receptor 1 Antibody Sales Value Share by Type, 2025 VS 2032
  32. 7.9.3 Italy Tachykinin Receptor 1 Antibody Sales Value Share by Application, 2025 VS 2032
  33. 7.10 Spain
  34. 7.10.1 Spain Tachykinin Receptor 1 Antibody Sales Value Growth Rate (2021-2032)
  35. 7.10.2 Spain Tachykinin Receptor 1 Antibody Sales Value Share by Type, 2025 VS 2032
  36. 7.10.3 Spain Tachykinin Receptor 1 Antibody Sales Value Share by Application, 2025 VS 2032
  37. 7.11 Russia
  38. 7.11.1 Russia Tachykinin Receptor 1 Antibody Sales Value Growth Rate (2021-2032)
  39. 7.11.2 Russia Tachykinin Receptor 1 Antibody Sales Value Share by Type, 2025 VS 2032
  40. 7.11.3 Russia Tachykinin Receptor 1 Antibody Sales Value Share by Application, 2025 VS 2032
  41. 7.12 Netherlands
  42. 7.12.1 Netherlands Tachykinin Receptor 1 Antibody Sales Value Growth Rate (2021-2032)
  43. 7.12.2 Netherlands Tachykinin Receptor 1 Antibody Sales Value Share by Type, 2025 VS 2032
  44. 7.12.3 Netherlands Tachykinin Receptor 1 Antibody Sales Value Share by Application, 2025 VS 2032
  45. 7.13 Nordic Countries
  46. 7.13.1 Nordic Countries Tachykinin Receptor 1 Antibody Sales Value Growth Rate (2021-2032)
  47. 7.13.2 Nordic Countries Tachykinin Receptor 1 Antibody Sales Value Share by Type, 2025 VS 2032
  48. 7.13.3 Nordic Countries Tachykinin Receptor 1 Antibody Sales Value Share by Application, 2025 VS 2032
  49. 7.14 China
  50. 7.14.1 China Tachykinin Receptor 1 Antibody Sales Value Growth Rate (2021-2032)
  51. 7.14.2 China Tachykinin Receptor 1 Antibody Sales Value Share by Type, 2025 VS 2032
  52. 7.14.3 China Tachykinin Receptor 1 Antibody Sales Value Share by Application, 2025 VS 2032
  53. 7.15 Japan
  54. 7.15.1 Japan Tachykinin Receptor 1 Antibody Sales Value Growth Rate (2021-2032)
  55. 7.15.2 Japan Tachykinin Receptor 1 Antibody Sales Value Share by Type, 2025 VS 2032
  56. 7.15.3 Japan Tachykinin Receptor 1 Antibody Sales Value Share by Application, 2025 VS 2032
  57. 7.16 South Korea
  58. 7.16.1 South Korea Tachykinin Receptor 1 Antibody Sales Value Growth Rate (2021-2032)
  59. 7.16.2 South Korea Tachykinin Receptor 1 Antibody Sales Value Share by Type, 2025 VS 2032
  60. 7.16.3 South Korea Tachykinin Receptor 1 Antibody Sales Value Share by Application, 2025 VS 2032
  61. 7.17 India
  62. 7.17.1 India Tachykinin Receptor 1 Antibody Sales Value Growth Rate (2021-2032)
  63. 7.17.2 India Tachykinin Receptor 1 Antibody Sales Value Share by Type, 2025 VS 2032
  64. 7.17.3 India Tachykinin Receptor 1 Antibody Sales Value Share by Application, 2025 VS 2032
  65. 7.18 Australia
  66. 7.18.1 Australia Tachykinin Receptor 1 Antibody Sales Value Growth Rate (2021-2032)
  67. 7.18.2 Australia Tachykinin Receptor 1 Antibody Sales Value Share by Type, 2025 VS 2032
  68. 7.18.3 Australia Tachykinin Receptor 1 Antibody Sales Value Share by Application, 2025 VS 2032
  69. 7.19 Southeast Asia
  70. 7.19.1 Southeast Asia Tachykinin Receptor 1 Antibody Sales Value Growth Rate (2021-2032)
  71. 7.19.2 Southeast Asia Tachykinin Receptor 1 Antibody Sales Value Share by Type, 2025 VS 2032
  72. 7.19.3 Southeast Asia Tachykinin Receptor 1 Antibody Sales Value Share by Application, 2025 VS 2032
  73. 7.20 Brazil
  74. 7.20.1 Brazil Tachykinin Receptor 1 Antibody Sales Value Growth Rate (2021-2032)
  75. 7.20.2 Brazil Tachykinin Receptor 1 Antibody Sales Value Share by Type, 2025 VS 2032
  76. 7.20.3 Brazil Tachykinin Receptor 1 Antibody Sales Value Share by Application, 2025 VS 2032
  77. 7.21 Argentina
  78. 7.21.1 Argentina Tachykinin Receptor 1 Antibody Sales Value Growth Rate (2021-2032)
  79. 7.21.2 Argentina Tachykinin Receptor 1 Antibody Sales Value Share by Type, 2025 VS 2032
  80. 7.21.3 Argentina Tachykinin Receptor 1 Antibody Sales Value Share by Application, 2025 VS 2032
  81. 7.22 Chile
  82. 7.22.1 Chile Tachykinin Receptor 1 Antibody Sales Value Growth Rate (2021-2032)
  83. 7.22.2 Chile Tachykinin Receptor 1 Antibody Sales Value Share by Type, 2025 VS 2032
  84. 7.22.3 Chile Tachykinin Receptor 1 Antibody Sales Value Share by Application, 2025 VS 2032
  85. 7.23 Colombia
  86. 7.23.1 Colombia Tachykinin Receptor 1 Antibody Sales Value Growth Rate (2021-2032)
  87. 7.23.2 Colombia Tachykinin Receptor 1 Antibody Sales Value Share by Type, 2025 VS 2032
  88. 7.23.3 Colombia Tachykinin Receptor 1 Antibody Sales Value Share by Application, 2025 VS 2032
  89. 7.24 Peru
  90. 7.24.1 Peru Tachykinin Receptor 1 Antibody Sales Value Growth Rate (2021-2032)
  91. 7.24.2 Peru Tachykinin Receptor 1 Antibody Sales Value Share by Type, 2025 VS 2032
  92. 7.24.3 Peru Tachykinin Receptor 1 Antibody Sales Value Share by Application, 2025 VS 2032
  93. 7.25 Saudi Arabia
  94. 7.25.1 Saudi Arabia Tachykinin Receptor 1 Antibody Sales Value Growth Rate (2021-2032)
  95. 7.25.2 Saudi Arabia Tachykinin Receptor 1 Antibody Sales Value Share by Type, 2025 VS 2032
  96. 7.25.3 Saudi Arabia Tachykinin Receptor 1 Antibody Sales Value Share by Application, 2025 VS 2032
  97. 7.26 Israel
  98. 7.26.1 Israel Tachykinin Receptor 1 Antibody Sales Value Growth Rate (2021-2032)
  99. 7.26.2 Israel Tachykinin Receptor 1 Antibody Sales Value Share by Type, 2025 VS 2032
  100. 7.26.3 Israel Tachykinin Receptor 1 Antibody Sales Value Share by Application, 2025 VS 2032
  101. 7.27 UAE
  102. 7.27.1 UAE Tachykinin Receptor 1 Antibody Sales Value Growth Rate (2021-2032)
  103. 7.27.2 UAE Tachykinin Receptor 1 Antibody Sales Value Share by Type, 2025 VS 2032
  104. 7.27.3 UAE Tachykinin Receptor 1 Antibody Sales Value Share by Application, 2025 VS 2032
  105. 7.28 Turkey
  106. 7.28.1 Turkey Tachykinin Receptor 1 Antibody Sales Value Growth Rate (2021-2032)
  107. 7.28.2 Turkey Tachykinin Receptor 1 Antibody Sales Value Share by Type, 2025 VS 2032
  108. 7.28.3 Turkey Tachykinin Receptor 1 Antibody Sales Value Share by Application, 2025 VS 2032
  109. 7.29 Iran
  110. 7.29.1 Iran Tachykinin Receptor 1 Antibody Sales Value Growth Rate (2021-2032)
  111. 7.29.2 Iran Tachykinin Receptor 1 Antibody Sales Value Share by Type, 2025 VS 2032
  112. 7.29.3 Iran Tachykinin Receptor 1 Antibody Sales Value Share by Application, 2025 VS 2032
  113. 7.30 Egypt
  114. 7.30.1 Egypt Tachykinin Receptor 1 Antibody Sales Value Growth Rate (2021-2032)
  115. 7.30.2 Egypt Tachykinin Receptor 1 Antibody Sales Value Share by Type, 2025 VS 2032
  116. 7.30.3 Egypt Tachykinin Receptor 1 Antibody Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Merck
  2. 8.1.1 Merck Company Information
  3. 8.1.2 Merck Business Overview
  4. 8.1.3 Merck Tachykinin Receptor 1 Antibody Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Merck Tachykinin Receptor 1 Antibody Product Portfolio
  6. 8.1.5 Merck Recent Developments
  7. 8.2 Boster Biological Technology
  8. 8.2.1 Boster Biological Technology Company Information
  9. 8.2.2 Boster Biological Technology Business Overview
  10. 8.2.3 Boster Biological Technology Tachykinin Receptor 1 Antibody Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Boster Biological Technology Tachykinin Receptor 1 Antibody Product Portfolio
  12. 8.2.5 Boster Biological Technology Recent Developments
  13. 8.3 United States Biological
  14. 8.3.1 United States Biological Company Information
  15. 8.3.2 United States Biological Business Overview
  16. 8.3.3 United States Biological Tachykinin Receptor 1 Antibody Revenue and Gross Margin (2021-2026)
  17. 8.3.4 United States Biological Tachykinin Receptor 1 Antibody Product Portfolio
  18. 8.3.5 United States Biological Recent Developments
  19. 8.4 Santa Cruz Biotechnology
  20. 8.4.1 Santa Cruz Biotechnology Company Information
  21. 8.4.2 Santa Cruz Biotechnology Business Overview
  22. 8.4.3 Santa Cruz Biotechnology Tachykinin Receptor 1 Antibody Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Santa Cruz Biotechnology Tachykinin Receptor 1 Antibody Product Portfolio
  24. 8.4.5 Santa Cruz Biotechnology Recent Developments
  25. 8.5 Proteintech
  26. 8.5.1 Proteintech Company Information
  27. 8.5.2 Proteintech Business Overview
  28. 8.5.3 Proteintech Tachykinin Receptor 1 Antibody Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Proteintech Tachykinin Receptor 1 Antibody Product Portfolio
  30. 8.5.5 Proteintech Recent Developments
  31. 8.6 ProSci
  32. 8.6.1 ProSci Company Information
  33. 8.6.2 ProSci Business Overview
  34. 8.6.3 ProSci Tachykinin Receptor 1 Antibody Revenue and Gross Margin (2021-2026)
  35. 8.6.4 ProSci Tachykinin Receptor 1 Antibody Product Portfolio
  36. 8.6.5 ProSci Recent Developments
  37. 8.7 NSJ Bioreagents
  38. 8.7.1 NSJ Bioreagents Company Information
  39. 8.7.2 NSJ Bioreagents Business Overview
  40. 8.7.3 NSJ Bioreagents Tachykinin Receptor 1 Antibody Revenue and Gross Margin (2021-2026)
  41. 8.7.4 NSJ Bioreagents Tachykinin Receptor 1 Antibody Product Portfolio
  42. 8.7.5 NSJ Bioreagents Recent Developments
  43. 8.8 LSBio
  44. 8.8.1 LSBio Company Information
  45. 8.8.2 LSBio Business Overview
  46. 8.8.3 LSBio Tachykinin Receptor 1 Antibody Revenue and Gross Margin (2021-2026)
  47. 8.8.4 LSBio Tachykinin Receptor 1 Antibody Product Portfolio
  48. 8.8.5 LSBio Recent Developments
  49. 8.9 GeneTex
  50. 8.9.1 GeneTex Company Information
  51. 8.9.2 GeneTex Business Overview
  52. 8.9.3 GeneTex Tachykinin Receptor 1 Antibody Revenue and Gross Margin (2021-2026)
  53. 8.9.4 GeneTex Tachykinin Receptor 1 Antibody Product Portfolio
  54. 8.9.5 GeneTex Recent Developments
  55. 8.10 FineTest
  56. 8.10.1 FineTest Company Information
  57. 8.10.2 FineTest Business Overview
  58. 8.10.3 FineTest Tachykinin Receptor 1 Antibody Revenue and Gross Margin (2021-2026)
  59. 8.10.4 FineTest Tachykinin Receptor 1 Antibody Product Portfolio
  60. 8.10.5 FineTest Recent Developments
  61. 8.11 Everest Biotech
  62. 8.11.1 Everest Biotech Company Information
  63. 8.11.2 Everest Biotech Business Overview
  64. 8.11.3 Everest Biotech Tachykinin Receptor 1 Antibody Revenue and Gross Margin (2021-2026)
  65. 8.11.4 Everest Biotech Tachykinin Receptor 1 Antibody Product Portfolio
  66. 8.11.5 Everest Biotech Recent Developments
  67. 8.12 Cusabio
  68. 8.12.1 Cusabio Company Information
  69. 8.12.2 Cusabio Business Overview
  70. 8.12.3 Cusabio Tachykinin Receptor 1 Antibody Revenue and Gross Margin (2021-2026)
  71. 8.12.4 Cusabio Tachykinin Receptor 1 Antibody Product Portfolio
  72. 8.12.5 Cusabio Recent Developments
  73. 8.13 Atlas Antibodies
  74. 8.13.1 Atlas Antibodies Company Information
  75. 8.13.2 Atlas Antibodies Business Overview
  76. 8.13.3 Atlas Antibodies Tachykinin Receptor 1 Antibody Revenue and Gross Margin (2021-2026)
  77. 8.13.4 Atlas Antibodies Tachykinin Receptor 1 Antibody Product Portfolio
  78. 8.13.5 Atlas Antibodies Recent Developments
  79. 8.14 Advanced Targeting Solutions
  80. 8.14.1 Advanced Targeting Solutions Company Information
  81. 8.14.2 Advanced Targeting Solutions Business Overview
  82. 8.14.3 Advanced Targeting Solutions Tachykinin Receptor 1 Antibody Revenue and Gross Margin (2021-2026)
  83. 8.14.4 Advanced Targeting Solutions Tachykinin Receptor 1 Antibody Product Portfolio
  84. 8.14.5 Advanced Targeting Solutions Recent Developments
9 Concluding Insights
    10 Appendix
    1. 10.1 Reasons for Doing This Study
    2. 10.2 Research Methodology
    3. 10.3 Research Process
    4. 10.4 Authors List of This Report
    5. 10.5 Data Source
    6. 10.5.1 Secondary Sources
    7. 10.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst